<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
Blogs

CU Cancer Center News and Stories

Immunotherapy

Research    Pancreatic Cancer    Immunotherapy    Surgery

Unleashing Immune-Cell Soldiers: Yuwen Zhu, PhD, Journeyed from China to Colorado in His Quest to Fight Cancer

Yuwen Zhu, PhD, grew up in a rural village in China. His mother couldn’t read. “I really didn’t know about college – even what the word meant,” he says.


Author Mark Harden | Publish Date May 26, 2024
Full Story

Research    Melanoma    Immunotherapy   

R01 Grant Will Help Find a Way to Overcome Resistance to Immunotherapy in Melanoma  

Melanoma cells can hide, but they can’t run from Eduardo Davila, PhD, associate director of cancer research training and education coordination at the University of Colorado Cancer Center


Author Greg Glasgow | Publish Date July 26, 2023
Full Story

Patient Care    Community    Immunotherapy    lymphoma    ColoradoSPH at CU Anschutz   

CU Cancer Center Member Gains Unique Perspective as Cancer Patient

For a significant portion of his career, Arnold Levinson, PhD, MJ, has done work related to cancer.


Author Rachel Sauer | Publish Date June 16, 2023
Full Story

Research    Blood Cancer    Immunotherapy    lymphoma

What is the Best Lymphoma Treatment After CAR T Therapy Fails? 

For 30% to 40% of lymphoma patients who receive CAR T therapy, the treatment is a godsend. Typically given to lymphoma patients for whom other treatments have proven ineffective, CAR T therapy involves removing immune cells from the body via a blood draw, reengineering them to become better cancer fighters, then reintroducing them to the bloodstream, where they seek out and destroy cancer cells. 


Author Greg Glasgow | Publish Date April 25, 2023
Full Story

Research    Community    Immunotherapy   

What is Immunotherapy? 

When it comes to treating cancer, doctors have many tools in their arsenal. For decades, cancer was treated with surgery, chemotherapy and radiation — broad tools that affect healthy cells along with the cancer cells they are meant to eradicate. 


Author Greg Glasgow | Publish Date January 11, 2023
Full Story

Research    Patient Care    Head and Neck Cancer    Clinical Trials    Immunotherapy

Clinical Trial Participation Helps Woman Diagnosed with Laryngeal Cancer Enjoy Every Day Without the Disease

Jane Hart is a lot of things: extremely proud mom of Shelby, daughter extraordinaire and apple of Jane’s eye. Dog mom to (deservedly spoiled) Maizy, Taco, Winnie, and Walter. Collector of Talavera pottery. Unabashed “Real Housewives of Salt Lake City” fan. A surprising 71, because she looks at least 10 years younger.

Cancer survivor – stage 4 laryngeal cancer that necessitated a tracheostomy and laryngectomy, that forced her to relearn how to breathe and talk.


Author Rachel Sauer | Publish Date December 16, 2022
Full Story

Head and Neck Cancer    Cancer    Oncology    Immunotherapy

Selective Nodal Radiation May Be a More Effective Approach in Cancer Treatment

A promising new study released by the University of Colorado Cancer Center suggests that recurrence of certain cancers can be significantly decreased by irradiating only a select set of lymph nodes near a tumor rather than all of them.


Author Laura Kelley | Publish Date November 16, 2022
Full Story

Patient Care    Ovarian Cancer    Immunotherapy    Genetics

Innovative Immunotherapy Treatment Helps Ovarian Cancer Patient See Amazing Results

People often tell Winona Williams that she’s brave, and she is. Ovarian cancer could easily become a dark cloud over her, shadowing every minute of every day.


Author Rachel Sauer | Publish Date September 20, 2022
Full Story

Research    Immunotherapy    lymphoma

Research Shows CAR T Cell Therapy Is Effective Second-Line Treatment for Large B-Cell Lymphoma

Large B-cell lymphoma (LBCL) is one of the most aggressive lymphomas and accounts for about 30% of all lymphoma diagnoses.


Author Rachel Sauer | Publish Date July 14, 2022
Full Story

Research    Lung Cancer    Immunotherapy

CU Cancer Center Researcher Focusing on Multiple Avenues of Immunoprevention for Lung Cancer

An exciting and innovative area of cancer research is immunoprevention, in which studies focus on preventing cancer before its onset by using vaccines, antibodies, and other immune mechanisms.


Author Rachel Sauer | Publish Date July 06, 2022
Full Story

Patient Care    Lung Cancer    Prostate Cancer    Melanoma    Immunotherapy   

Acknowledging the Fears of Cancer by Giving Them a Face and a Name

To understand why Beau Gill built a mental cupboard for Jeff and Spike, first you must travel back with him to the small town of Catemaco in Mexico’s state of Veracruz.


Author Rachel Sauer | Publish Date April 20, 2022
Full Story

Immunotherapy

Immunotherapy and HDAC inhibition are anti-cancer besties

Immunotherapies have revolutionized the care of many cancers, teaching the body’s own immune cells to recognize and attack tumor cells. Leading the way are drugs known as checkpoint inhibitors, which block a kind of “white flag” that tumors wave as a peace signal to T cells that would very much like to kill them. Really, this white flag is a protein called PD-L1 – many tumors coat themselves in it. When PD-L1 on the surface of a cancer cell sees its partner, PD1, on T cells, these T cells are tricked into letting the cancer cell live. To counteract this dirty trick, checkpoint inhibitor drugs block the functions of PD-L1 on tumor cells (e.g. atezolizumab) or PD1 on T cells (e.g. pembrolizumab), allowing T cells to go about their cancer-killing business.


Author Cancer Center | Publish Date June 24, 2019
Full Story

Melanoma    Immunotherapy

Is your melanoma hot enough for immunotherapy?

Melanomas tend to be “hot” or “cold” – if they’re hot, immunotherapy lights melanoma tumors like beacons for elimination by the immune system; but 40-50 percent of melanomas are cold, making them invisible to the immune system, and patients with cold tumors tend to show little benefit from immunotherapies. The problem is that it’s been impossible to distinguish a hot melanoma from a cold one – the solution has been to administer immunotherapy and hope for the best, often leading to wasted time and resources. Now a University of Colorado Cancer Center study presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 identifies a possible way to predict which melanomas are hot and cold: Tumors with mutations in genes leading to over-activation of the NF-kB signaling pathway were more than three times as likely to respond to anti-PD1 immunotherapy compared with tumors in which these changes were absent.


Author Cancer Center | Publish Date April 02, 2019
Full Story

CU Cancer Center In the News

News Medical

Study shows effectiveness of treating pancreatic cancer patients with chemotherapy before surgery

news outletNews Medical
Publish DateJune 19, 2024

A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.

Full Story
Cancer Network

Liso-cel May Show Benefit in Earlier Therapy Lines for Lymphoma Subgroups

news outletCancer Network
Publish DateJune 14, 2024

In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.

Full Story
Cancer Health

2024 Cancer Health 25: People Who Power Clinical Trials

news outletCancer Health
Publish DateJune 11, 2024

This year's Cancer Health 25 highlights the transformative power and promise of clinical trials. University of Colorado Cancer Center member Jessica McDermott, MD, MSCS, is leading clinical trials at both the CU Cancer Center and the Rocky Mountain Regional Veterans Affairs Medical Center. Additionally, she serves as the CU Cancer Center's deputy associate director for diversity and inclusion in clinical research.

Full Story
Cancer Network

Learning to “Aim High” Within Male-Dominated Fields in Public Health

news outletCancer Network
Publish DateJune 10, 2024

Cathy Bradley, PhD, deputy director of the University of Colorado Cancer Center and dean of the Colorado School of Public Health, is a trailblazer in health economics. At a Breaking Barriers: Women in Oncology discussion, she shared insights on overcoming challenges as a woman in a male-dominated field and discussed her research on the impact of employment on cancer patients' health insurance decisions.

Full Story